Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases

The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non‐oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non‐oncological diseases and (b) the risk–benefit ratio of treating p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Pharmacol
Main Authors: Berger, Nathan A, Besson, Valerie C, Boulares, A Hamid, Bürkle, Alexander, Chiarugi, Alberto, Clark, Robert S, Curtin, Nicola J, Cuzzocrea, Salvatore, Dawson, Ted M, Dawson, Valina L, Haskó, György, Liaudet, Lucas, Moroni, Flavio, Pacher, Pál, Radermacher, Peter, Salzman, Andrew L, Snyder, Solomon H, Soriano, Francisco Garcia, Strosznajder, Robert P, Sümegi, Balázs, Swanson, Raymond A, Szabo, Csaba
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Themed Section: Review Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5758399/
https://ncbi.nlm.nih.gov/pubmed/28213892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13748
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados